Skip to main content
SpringerLink
Log in

Prevalence and Incidence of Arrhythmias and Sudden Death in Heart Failure

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Patients with heart failure are prone to a variety of arrhythmias, symptomatic and asymptomatic, that are prognostically significant and have an important bearing on the management of these patients. However there are some inherent problems in assessing the frequency of these arrhythmias within a large patient population, due to a lack of uniformity in defining heart failure and the transient nature of these rhythms. Patients with heart failure commonly die suddenly. The causes of these deaths are difficult to ascertain accurately and are often presumed arrhythmic. With the advent of effective interventions to prevent sudden death, accurately defining the causal relationship between the arrhythmias and sudden death has assumed great importance to appropriately target therapy. Several attempts have been made to predict such deaths on the basis of non-invasive and invasive diagnostic investigations with variable success. In this article we review the incidence and prevalence of atrial and ventricular arrhythmias and sudden deaths in epidemiological studies, surveys and randomised control trials of patients with heart failure. We discuss the prognostic significance of these arrhythmias, the inherent problems in their diagnosis and whether their presence predicts the risk of sudden deaths and the mode of such deaths in the heart failure population. The role of various investigations in risk stratification of sudden death has also been discussed

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Khand A, Rankin AC, Kaye GC, Cleland JGF. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J2000;21:61–632.

    Google Scholar 

  2. Cleland JGF, Thackray S, Goodge L, Kaye GC, Cooklin M. Outcome studies with device therapy in patients with heart failure. J Cardiovasc Electrophysiol2002;13: (1 Suppl):S7–91.

    Google Scholar 

  3. Teerlink JR, Jalaluddin M, Anderson S, et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. Circulation2000;101:4–46.

    Google Scholar 

  4. Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 1993;87:VI–VI16.

    Google Scholar 

  5. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:87–883.

    Google Scholar 

  6. Anderson JL, Platia EV, Hallstrom A, et al. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction: A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Circulation1994;90:284–2852.

    Google Scholar 

  7. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo-The Cardiac Arrhythmia Suppression Trial. New Engl J Med1991;324:78–788.

    Google Scholar 

  8. Greenberg HM, Dwyer Jr EM, Hochman JS, Steinberg JS, Echt DS, Peters RW. Interaction of ischaemia and encainide/flecainide treatment: A proposed mechanism for the increased mortality in CAST I. Br Heart J 1995;74:63–635.

    Google Scholar 

  9. Cleland JGF. Screening for left ventricular dysfunction and chronic heart failure: Should it be done and, if so, how? Dis Manage Health Outcomes1997;4:169-184.

    Google Scholar 

  10. Cleland J, Swedberg K., Cohen Solal A, et al. The Euro-Heart Failure Survey of the EUROHEART Survey Programme: A survey on the quality of care among patients with heart failure in Europe. Eur J Heart Fail 2000;2:12–132.

    Google Scholar 

  11. Cleland JGF, Swedberg K, Follath F, Widimsky J. The IMPROVEMENT of heart failure survey. International variations in the aetiology of heart failure managed in primary care. Eur J Heart Fail2001;3:S72(Abstract).

    Google Scholar 

  12. Cleland JGF, Khand A, Clark AC. The heart failure epidemic: Exactly how big is it? Eur Heart J2001;22:62– 626.

    Google Scholar 

  13. Davies MK, Hobbs FDR, Davis RC, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening Study: A population based study. The Lancet 2001;358:439-444.

    Google Scholar 

  14. Senges JC, Becker R, Schreiner KD, et al. Variability of Holter electrocardiographic findings in patients fulfilling the noninvasive MADIT criteria. Multicenter Automatic Defibrillator Implantation Trial. Pacing Clin Electrophysiol 2002;25:18–190.

    Google Scholar 

  15. Middlekauf HR, Stevenson WG, Warner-Stevenson L, Saxon LA. Syncope in advanced heart failure: High risk of sudden death regardless of origin of syncope. J AmColl Cardiol1993;21:11–116.

    Google Scholar 

  16. Fruhwald FM, Eber B, Schumacher M, et al. Syncope in dilated cardiomyopathy is a predictor of sudden cardiac death. Cardiology1996;87:17–180.

    Google Scholar 

  17. Fonarow GC, Feliciano Z, Boyle NG, et a Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverterdefibrillator. Am J Cardiol2000;85:98–985.

    Google Scholar 

  18. Cleland JGF, Thygesen K, Uretsky BF, et al. Cardiovascular critical event pathways for the progression of heart failure. A report from the ATLAS study. Eur Heart J 2001;22:160–1612.

    Google Scholar 

  19. Cleland JGF, Massie BM, Packer M. Sudden death in heart failure: Vascular or electrical? Eur J Heart Fail 1999;1:4–45.

    Google Scholar 

  20. Wilkoff BL, Kuhlkamp V, Volosin K, et al. Critical analysis of dual-chamber implantable cardioverter-defibrillator arrhythmia detection. Circulation2001;103:381.

    Google Scholar 

  21. Sticherling C, Schaumann A, Hohnloser SH. First worldwide clinical experience with a new dual chamber implantable cardioverter defibrillator. Advantages and complications. The Ventak AV II DR Investigators. Europace 1999;1:9–102.

    Google Scholar 

  22. Wood MA, Stambler BS, Greenway P, Ellenbogen K. Lessons learnd from data logging in a multicenter clinical trial using a late-generation implantable cardioverterdefibrillator. The Guardian ATP 4210 Multicenter Investigations Group. J Am Coll Cardiol1994;24:169– 1699.

    Google Scholar 

  23. Connolly SJ, Hallstrom AP, Cappato R, et al. Metaanalysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J2000;21(24):207– 2078.

    Google Scholar 

  24. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy. Circulation2002;105:1453.

    Google Scholar 

  25. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet1999;333:200–2007.

    Google Scholar 

  26. Kjekshus J. Arrhythmias and mortality in congestive heart failure. Am J Cardiol1990;65:42 I-48 I

    Google Scholar 

  27. Hallstrom A, Pratt CM, Greene L, et al. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: Analysis of the cardiac arrhythmia suppression trial. J Am Coll Cardiol1995;25:125–1257.

    Google Scholar 

  28. Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation1989;80:167–1680.

    Google Scholar 

  29. Mosterd A, Hoes AW, Bruijne de MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population. The Rotterdan Study. Eur Heart J 1999;20:44–455.

    Google Scholar 

  30. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J2001;22:131–1327.

    Google Scholar 

  31. Khand AU, Gemmell I, Rankin AC, Cleland JGF. Clinical events leading to the progression of heart failure: Insights from a national database of hospital discharges. Eur Heart J2001;22:15–164.

    Google Scholar 

  32. Yusuf S, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. New Engl J Med1992;327:68–691.

    Google Scholar 

  33. Yusuf S, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl J Med1991;325: 29–302.

    Google Scholar 

  34. Cohn JN, Tognoni G. For the Valsartan Heart Failure Trial Investigators. Arandomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure.NEngl J Med2001;345:166–1675.

    Google Scholar 

  35. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure: The V-HeFT studies. Circulation1993;87:VI10–VI110.

    Google Scholar 

  36. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study. New Engl J Med1986;314:154–1552.

    Google Scholar 

  37. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New Engl J Med1991;325:30–310.

    Google Scholar 

  38. Cohn JN, Tognoni G, Glazer RD, Spormann D. Baseline demographics of the valsartan heart failure trial. Eur J Heart Failure2000;2:439-446.

    Google Scholar 

  39. Fletcher RD, Cintron GB, Johnson G, Orndorff J, Carson P, Cohn JN. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. Circulation1993;87:VI49-VI55.

    Google Scholar 

  40. Goldman S, Johnson G, Cohn JN, Cintron G, Smith R, Francis G. Mechanism of death in heart failure: The Vasodilator-Heart Failure Trials. Circulation 1993;87:VI2–VI31.

    Google Scholar 

  41. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. New Engl J Med1991;325:146–1475.

    Google Scholar 

  42. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl J Med1996;334:1349- 1355.

    Google Scholar 

  43. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. New Engl J Med1996;335:110–1114.

    Google Scholar 

  44. Packer M, Poole Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensinconverting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:231–2318.

    Google Scholar 

  45. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. New Engl J Med2001;344:165–1658.

    Google Scholar 

  46. O'Connor CM, Belkin RN, Carson PE, et al. Effect of amlodipine on mode of death in severe chronic heart failure: the PRAISE trial. Circulation1995;92 (Supp. I):– 143(Abstract).

    Google Scholar 

  47. Cohn JN, Goldstein SO, Greenberg BH, et al. A dosedependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med1998;339:181–1816.

    Google Scholar 

  48. Pitt B, Poole-Wilson PA, Segal R, et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: Rationale, design and baseline characteristics of patients in the Losartan Heart Failure Survival Study-ELITE II. J Card Fail1999;5:14–154.

    Google Scholar 

  49. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med1999;341:709-717.

    Google Scholar 

  50. Pitt B, Poole Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:158–1587.

    Google Scholar 

  51. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. New Engl J Med1997;336:52–533.

    Google Scholar 

  52. CIBIS-II Investigators and Committee. The Cardiac insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet1999;353:9-13.

    Google Scholar 

  53. Singh SN, Fisher SG, Carson PE, Fletcher RD, and the Department of Veterans Affairs CHF STAT Investigators. Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure with vasodilator therapy. J Am Coll Cardiol1998;32:94–947.

    Google Scholar 

  54. Hampton JR, Van Veldhuisen D, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet1997;349:97–977.

    Google Scholar 

  55. Doval HC, Nul DR, Grancelli HI, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet1994;344:49– 498.

    Google Scholar 

  56. Swedberg K, Idanpaan Heikkila U, Remes J, for the CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl J Med.1987;316:1429- 1435.

    Google Scholar 

  57. Doval HC, Nul DR, Grancelli HO, et al. Nonsustained ventricular tachycardia in severe heart failure. Circulation 1996;94:319–3203.

    Google Scholar 

  58. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality ON dofetilide (DIAMOND) substudy. Circulation2001;104:29–296.

    Google Scholar 

  59. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl JMed1999;341:85–865.

    Google Scholar 

  60. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. New Engl J Med 2001;344:1659-1667.

    Google Scholar 

  61. Cleland JGF, Armstrong P, Horowitz JD, et al. Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. Eur J Heart Failure1999;1:7–79.

    Google Scholar 

  62. Andersson B, Caidahl K, Waagstein F. An echocardiographic evaluation of patients with idiopathic heart failure. Chest1995;107(3):68–689.

    Google Scholar 

  63. McDermott MM, Feinglass J, Sy J, Gheorghiade M. Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: Clinical characteristics and drug therapy. Am JMed 1995;99:629-635.

    Google Scholar 

  64. McAlister FA, Teo KK, Taher M, et al. Insights into the contemporary epidemiology and outpatient manageemnt of congestive heart failure. Am Heart J1999;138:8–94.

    Google Scholar 

  65. Crijns HJGM, Tjeersdsma PJ, de Kam P-J, et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J2001;21:123–1245.

    Google Scholar 

  66. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and haemodynamic changes in patients with chronic heart failure: A prospective study in 344 patients with baseline sinus rhythm. JACC 1998;32:19–204.

    Google Scholar 

  67. Pratt CM, Gardner M, Pepine C, et al. Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure. Am J Cardiol1995;75:124–1249.

    Google Scholar 

  68. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. New Engl J Med1995;333:7– 82.

    Google Scholar 

  69. Gall NP, Zaman A, O'Nunain S, Fox KA, Flapan A, Nolan J. Implementation of the NICE guidelines for the primary prevention of mortality from ventricular tachyarrhythmias: Implications forUKelectrophysiology centres; activity modelling from the UK-HEART study. Heart 2001;86:219-220.

    Google Scholar 

  70. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: Results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998;98:151–1516.

    Google Scholar 

  71. Cleland JGF, Dargie HJ, Ford I. Mortality in heart failure: Clinical variables of prognostic value. Br Heart J 1987;58:57–582.

    Google Scholar 

  72. Tofler GH, Gebara OC, Mittleman MA, et al. Morning peak in ventricular tachyarrhythmias detected by time of implantable cardioverter/defibrillator therapy. Circulation 1995;92:120–1208.

    Google Scholar 

  73. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, et al. Effects of controlled-release metoprolol on total mortality, hospitalization, and well-being in patients with heart failure: The metoprolol CR-XL randomized intervention trial in congestive heart failure (MERITHF). JAMA2000;283:129–1302.

    Google Scholar 

  74. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in the Framingham heart study subjects. Circulation 1993;88:10–115.

    Google Scholar 

  75. Croft JB, Giles WH, Pollard RA, Keenan NL, Casper ML, Anda RF. Heart failure survival among older adults in the United States: A poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999;159:50–510.

    Google Scholar 

  76. Cleland JGF, Erhardt L, Murray G, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. Eur Heart J1997;18:4–51.

    Google Scholar 

  77. Cowburn PJ, Cleland JGF, Coats AJS, Komajda M. Risk stratification in chronic heart failure. Eur Heart J 1998;19:69–710.

    Google Scholar 

  78. Komajda M, Jais JP, Reeves B, et al. Factors predicting mortality in idiopathic dilated cardiomyopathy. Eur Heart J1990;11:82–831.

    Google Scholar 

  79. Warner-Stevenson L, Fowler MB, Schroeder JS, Stevenson WG, Dracup KA, Fond V. Poor survival of patients with idiopathic cardiomyopathy considered too well for transplantation. Am J Med1987;83:87–876.

    Google Scholar 

  80. Stevenson WG, Middlekauf HR, Stevenson LW, et al. Significance of aborted cardiac arrest and sustained ventricular tachycardia in patients referred for treatment of advanced heart failure. Am Heart J1992;124:12–130.

    Google Scholar 

  81. De Maria R, Gavazzi A, Caroli A, et al. Ventricular arrhythmias in dilated cardiomyopathy as an independent prognostic hallmark. Am J Cardiol1992;69:145–1457.

    Google Scholar 

  82. Olshausen KV, Steinen U, Math D, et al. Long term prognostic significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1988;61:14–151.

    Google Scholar 

  83. Reese DB, Silverman ME, Gold MR, Gottlieb SS. Prognostic importance of the length of ventricular tachycardia in patients with nonischaemic congestive heart failure. Am Heart J1995;130:489-493.

    Google Scholar 

  84. Unverferth DV, Magorien RD, Moeschberger ML, et al. Factors influencing the one year mortality of dilated cardiomyopathy. Am J Cardiol1984;54:14–152.

    Google Scholar 

  85. CIBIS Investigations and Committees. A randomized trial of B-blockade in heart failure. The Cardiac Insuffiency Bisoprolol Study (CIBIS). Circulation 1994;90:176–1773.

    Google Scholar 

  86. Wilson JR, Schwartz JS, Sutton MS, et al. Prognosis in severe heart failure:Relation to hemodynamic measurements and ventricular ectopic activity. JACC1983;2:40–410.

    Google Scholar 

  87. Soifer S, Nul DR, Grancelli HO, et al. Different predictors in sudden or progressive heart failure death in severe heart failure. JACC1997;29:247A(Abstract).

    Google Scholar 

  88. Gomes JA, Mehta D, Ip J, et al. Predictors of long-term survival in patients with malignant ventricular arrhythmias. Am J Cardiol1997;79:105–1060.

    Google Scholar 

  89. Massie BM, Podrid PJ, Hendrix GH, et al. Does asymptomatic worsening of arrhythmia predict sudden death in heart failure? Evidence for clinically significant proarrhythmia during milrinone therapy(Abstract). JACC 1992;19:78A.

    Google Scholar 

  90. Brembilla-Perrot B, Terrier de la Chasse A, Jacquemin L, Beurrier D, Houplon P. The signal-averaged electrocardiogram is of limited value in patients with bundle branch block and dilated cardiomyopathy in predicting inducible ventricular tachycardia or death. Am J Cardiol 1997;79:15–159.

    Google Scholar 

  91. Gonska BD, Bethge KP, Figulla HR, Kreuzer H. Occurence and clinical significance of endocardial late potentials and fractionations in idiopathic dilated cardiomyopathy. Br Heart J1988;59:39-46.

    Google Scholar 

  92. Mancini DM, Wong KL, Simson MB. Prognostic value of an abnormal signal-averaged electrocardiogram in patients with nonischemic congestive cardiomyopathy. Circulation1993;87:108–1092.

    Google Scholar 

  93. Ohnishi Y, Inoue T, Fukuzaki H. Value of the signalaveraged electrocardiogram as a predictor of sudden death in myocardial infarction and dilated cardiomyopathy. Jpn Circ1990;54:12–136.

    Google Scholar 

  94. Poll DS, Marchlinski FE, Falcone RA, Josephson ME, Simson MB. Abnormal signal-averaged electrocardiograms in patients with nonischemic congestive cardiomyopathy: Relationship to sustained ventricular tachyarrhythmias. Circulation1985;72:130–1313.

    Google Scholar 

  95. Silverman ME, Pressel MD, Brackett JC, et al. Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. Am J Cardiol1995;75:46–464.

    Google Scholar 

  96. Turrito G, Ahuja RK, Caref EB, El-Sherif N. Risk stratification for arrhythmic events in patients with nonischaemic dilated cardiomyopathy and nonsustained ventricular tachycardia: Role of programmed ventricular stimulation and the signal averaged electrocardiogram. JACC1994;24:152–1528.

    Google Scholar 

  97. Keeling PJ, Kulakowski P, Yi G, Slade AKB, Bent SE, McKenna WJ. Usefulness of signal-averaged electrocardiogram in idiopathic dilated cardiomyopathy for identifying patients with ventricular arrhythmias. Am J Cardiol1993;72:7–84.

    Google Scholar 

  98. Denereaz D, Zimmerman M, Adamec R. Significance of ventricular late potentials in non-ischaemic dilated cardiomyopathy. Eur Heart J1992;13:89–901.

    Google Scholar 

  99. Yi G, Keeling PJ, Goldman JH, Jian H, Poloniecki J, McKenna WJ. Prognostic significance of spectral turbulence analysis of the signal-averaged electrocardiogram in patients with idiopathic dilated cardiomyopathy. Am J Cardiol1995;75:49–497.

    Google Scholar 

  100. Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious arrhythmic events after myocardial infarction: Signal-averaged electrocardiogram, holter monitoring and radio-nuclide ventriculography. J Am Coll Cardiol 1987;9:53–538.

    Google Scholar 

  101. Bigger JTJ, Whang W, Rottman JN, et al. Mechanisms of death in the CABG Patch Trial. A randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary bypass graft surgery. Circulation1999;99:141–1421.

    Google Scholar 

  102. Bigger JT, for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. New Engl J Med1997;337:1569-1575.

    Google Scholar 

  103. Galinier M, Albenque JP, Afchar, et al. Prognostic value of late potentials in patients with congestive heart failure. Eur Heart J1996;17:26–271.

    Google Scholar 

  104. Middlekauf HR, Stevenson WG, Woo MA, et al. Comparison of frequency of late potentials in idiopathic dilated cardiomyopathy and ischemic cardiomyopathy with advanced congestive heart failure and their usefulness in predicting sudden death. Am J Cardiol1990;66:111– 1117.

    Google Scholar 

  105. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet1994;343:32–329.

    Google Scholar 

  106. Pinsky DJ, Sciacca RR, Steinberg JS. QT Dispersion as a marker of risk in patients awaiting heart transplantation. JACC1997;29:157–1584.

    Google Scholar 

  107. Brendorp B, et al. Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure. Eur J Heart Failure2002;4:20–206.

    Google Scholar 

  108. Zareba W, et al. Dispersion of ventricular repolarisation and arrhythmic death in coronary artery disease. Am J Cardiol2002;74:55–553.

    Google Scholar 

  109. Fei L, Goldman JH, Prasad K, et al. QT dispersion and RR variations on 1–lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J1996;17:25–263.

    Google Scholar 

  110. Grimm W, Steder U, Menz V, et al. QT dispersion and arrhythmic events in idiopathic dilated cardiomyopathy. Am J Cardiol1996;78:45–461.

    Google Scholar 

  111. Brooksby P, Batin PD, Nolan J, et al. The relationship between QT intervals and mortality in ambulant patients with chronic heart failure. The United Kingdom heart failure evaluation and assessment of risk trial (UKHEART). Eur Heart J1999;20:129–1292.

    Google Scholar 

  112. Fu GS, Meissner A, Simon R. Repolarization dispersion and sudden cardiac death in patients with impaired left ventricular function. Eur Heart J1997;18:28– 289.

    Google Scholar 

  113. Meinertz T, Treese N, Kasper W, et al. Determinants of prognosis in idiopathic dilated cardiomyopathy as determined by programmed electrical stimulation. Am J Cardiol 1985;56:33–341.

    Google Scholar 

  114. Milner PG, DiMarco JP, Lerman BB. Electrophysiological evaluation of sustained ventricular tachyarrhythmias in idiopathic dilated cardiomyopathy. PACE1988;11:56– 568.

    Google Scholar 

  115. Stevenson WG, Stevenson LW, Weiss J, Tillisch JH. Inducible ventricular arrhythmias and sudden death during vasodilator therapy of severe heart failure. Am Heart J1988;116:144–1454.

    Google Scholar 

  116. Chen X, Shenasa M, Borggrefe M, et al. Role of programmed ventricular stimulation in patients with idiopathic dilated cardiomyopathy and documented sustained ventricular tachyarrhythmias: Inducibility and prognosis value in 102 patients. Eur Heart J1994;15:7– 82.

    Google Scholar 

  117. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med1999;341:188– 1890.

    Google Scholar 

  118. Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter unsustained tachycardia trial investigators. N Engl J Med 2000;342:193–1945.

    Google Scholar 

  119. Sager PT, Choudhary R, Rahimtoola SH, Bhandari AK. The long-term prognosis of patients with out-of-hospital cardiac arrest but no inducible ventricular tachycardia. Am Heart J1990;120:133–1342.

    Google Scholar 

  120. Lindsay BD, Osborn JL, Schechtman KB, et al. Prospective detection of vulnerability to sustained ventricular tachycardia in patients awating cardiac transplantation. Am J Cardiol1992;69:619-624.

    Google Scholar 

Download references

Authors
  1. John G.F. Cleland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sudipta Chattopadhyay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aleem Khand
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Timothy Houghton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gerald C. Kaye
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cleland, J.G., Chattopadhyay, S., Khand, A. et al. Prevalence and Incidence of Arrhythmias and Sudden Death in Heart Failure. Heart Fail Rev 7, 229–242 (2002). https://doi.org/10.1023/A:1020024122726

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1020024122726

Search

Navigation